Remicade to infliximab biosimilar switches fare well in real-life practice

GLASGOW – Switching patients on the anti–tumor necrosis factor drug Remicade to a biosimilar infliximab product resulted in good efficacy and tolerability with substantial cost savings in two...
Source: Rheumatology News - Category: Rheumatology Source Type: research
More News: Remicade | Rheumatology